Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2007

View Archived Issues

Recent patents impart new therapeutic agents for respiratory and allergic disorders

Novel therapeutic agents for cardiovascular disorders imparted by pSivida

Novel 5-HT2C antagonist developed at BMS for the treatment of obesity

Recent patents report new treatments for neuropsychiatric disorders

New treatment option for urological disorders reported by Takeda

Mepolizumab lowers blood eosinophils and reduces steroid use in hypereosinophilic syndrome

Icatibant effective in acute hereditary angioedema attacks

Andolast prevents bronchoconstriction in asthma patients

BioMarin recaps Q4 events

NextPharma signs development agreement with Eucodis

Plethora plans phase III program for Invicorp in erectile dysfunction

VGX Pharmaceuticals and Advisys sign merger agreement

Progress in Avalon and Novartis' drug discovery collaboration

Lilly plans new phase III trial of Xigris

Enrollment open in phase III study of Stimuvax for NSCLC

Merck KGaA holds nearly all voting rights in Merck Serono

Ortec begins PMA supplement filing for OrCel

Amazon Biotech preparing phase I/II studies for AMZ-0026

Bristol-Myers Squibb and Adnexus to develop oncology compounds

Novelix licenses NVX-207 to AOP Orphan

Trius acquires rights to Dong-A's oxazolidinone antibacterial compounds

Phase III study of glufosfamide in pancreatic cancer misses endpoint

Positive phase I findings for LCP-AtorFen

Takeda and TAP sign promotion agreement for Amitiza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...